Lv4
418 积分 2022-07-28 加入
Drug Dosing in Patients Undergoing Therapeutic Plasma Exchange
3小时前
已完结
Drug Dosing in Patients Undergoing Therapeutic Plasma Exchange
1天前
已完结
Moving towards personalized treatments of immune-related adverse events
3天前
已完结
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
5天前
已完结
Journal of Trauma and Acute Care Surgery
1个月前
已完结
Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity
2个月前
已完结
OA03.04 A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions
3个月前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
4个月前
已完结
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors
6个月前
已完结
Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity
6个月前
已完结
皖公网安备34019202002308
